SEK 9.98
+0.24 (+2.46%)
SEK · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where XBRANE.ST is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional · 1 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMDNCT03805100results2023-11-13Change in Best Corrected Visual Acuity (BCVA)Randomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Ranibizumab | Macular Degeneration | 582 | 2021-05-11actual | 2023-11-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19